ProCE Banner Activity

Cancer Conversations™: PARP Inhibitors in Ovarian Cancer

Slideset Download
Download these slides from a live webinar to learn how to optimally manage ovarian cancer leveraging PARP inhibitors.

Released: October 18, 2021

Expiration: October 17, 2022

Share

Faculty

Robert E. Coleman

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Kathleen N. Moore

Kathleen N. Moore, MD, MS, FASCO

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director, Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Faculty Disclosure

Primary Author

Robert E. Coleman, MD, FRCP

Professor and Honorary Consultant Medical Oncologist
Cancer Clinical Trials Centre
Academic Unit of Clinical Oncology
Weston Park Hospital
Sheffield, England

Kathleen N. Moore, MD, MS, FASCO

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director, Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma